Molecular Biology of Blood Coagulation

Johannes Oldenburg; Rainer Schwaab

doi:10.1055/s-2001-16885

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2001; 27(4): 313-324
DOI: 10.1055/s-2001-16885

Molecular Biology of Blood Coagulation

Johannes Oldenburg, Rainer Schwaab

Institute for Experimental Hematology and Transfusion Services, University Clinics, Bonn, Germany

Abstract

ABSTRACT

A complex network of hemostasis proteins maintains the blood flow and integrity of the vascular system. Molecular biology techniques have led to identification and cloning of the corresponding genes, thereby providing the basis for development of various recombinant clotting factor concentrates. Further analysis of these genes allowed for phenotype and genotype correlations in patients with hemorrhagic or thromboembolic disorders and analysis of structure and function relationships of the involved proteins. All these efforts result in a greatly advanced understanding of the hemostatic network. The aim of this article is to illustrate this progress by reporting on the recent results in representative hereditary hemorrhagic and such thromboembolic conditions as hemophilia, von Willebrand disease, and thrombotic disorders.

KEYWORD

Blood coagulation factors - factor VIII - hemophilia A - genotype-phenotype correlation - structure-function relationships

Full Text

References

REFERENCES

1 Lane D A, Grant P J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood . 2000; 95 1517-1532
2 Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
3 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
4 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden/activated protein C resistance. Blood . 1995; 85 1504-1508
5 Toole J J, Knopf J L, Wozney J M. Molecular cloning of a cDNA encoding human antihaemophiliac factor. Nature . 1984; 312 342
6 Vehar G A, Keyt B, Eaton D. Structure of human factor VIII. Nature . 1984; 312 337-342
7 Pittman D D, Alderman E M, Tomkinson K N. Biochemical, immunological, and in vivo functional characterization of the B-domain deleted factor VIII. Blood . 1993; 81 2925-2935
8 Levinson B, Kenwrick S, Lakich D, Hammonds G, Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics . 1990; 7 1-11
9 Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics . 1992; 14 585-589
10 Naylor J A, Green P M, Pizza C R, Gianelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet . 1993; 2 11-17
11 Lakich D, Kazazian Jr H H, Antonarakis S E, Gitschier J. Inversions disrupting the factor VIII gene as a common cause of severe hemophilia A. Nat Genet . 1993; 5 236-241
12 Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001 (in press).
13 Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid haemophilia A molecular diagnosis by a simple DNA sequencing procedure: Identification of 144 novel mutations. Thromb Haemost 2001 (in press).
14 Pattinson J K, Millar D S, McVey J H. The molecular genetic analysis of hemophilia A: A direct search strategy for the detection of point mutations in the factor VIII gene. Blood . 1990; 76 2242-2248
15 Kemball-Cook G, Tuddenham E GD, Wacey A I. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res . 1998; 26 216-219
16 Becker J, Schwaab R, Möller-Taube A. Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: Family studies indicate a mutation type dependent sex ratio of mutation frequencies. Am J Hum Genet . 1996; 58 657-670
17 Schwaab R, Oldenburg J, Schwaab U. Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br J Haematol . 1995; 91 458-464
18 Schwaab R, Brackmann H H, Meyer C. Haemophilia A. Mutation type determines risk of inhibitor formation. Thromb Haemost . 1995; 74 1402-1406
19 Oldenburg J, Brackmann H H, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica . 2000; 85(Suppl) 7-14
20 Young M, Inaba H, Hoyer L W. Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet . 1997; 60 565-573
21 Oldenburg J, Schröder J, Schmitt C, Brackmann H H, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A genotype. Thromb Haemost . 1998; 79 452-453
22 Nichols W C, Amano K, Cacheris P M. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood . 1996; 88 1183-1187
23 Lee D H, Walker I R, Teitel J. Effect of the factor V Leiden mutation on the clinical expression of severe haemophilia A. Thromb Haemost . 2000; 83 387-391
24 Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood . 1990; 75 20-26
25 Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The ``Normandy'' variant of the von Willebrand disease: Characterization of a point mutation in the von Willebrand factor gene. Blood . 1991; 77 1937-1941
26 Nichols W C, Seligsohn U, Zivelin A. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell . 1998; 93 61-70
27 Pemberton S, Lindley P, Zaitsev V. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood . 1997; 89 2413-2421
28 Gale A J, Pellequer J-L, Getzoff E D, Griffin J H. Structural basis for hemophilia A caused by mutations in the C domains of blood coagulation factor VIII. Thromb Haemost . 2000; 83 78-85
29 Pratt K P, Shen B W, Takeshima K. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature . 1999; 402 439-441
30 Stoylova S S, Lenting P J, Kemball-Cook G, Holzenburg A. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem . 1999; 51 36573-36578
31 Oldenburg J, Brackmann H H, Schwaab R. Molecular genetics in haemophilia A. Vox Sang . 2000; 2(Suppl) 33-38
32 Jacquemin M, Laved'homme R, Benhida A. A novel cause of mild/moderate haemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood . 2000; 96 958-965
33 Liu M L, Shen B W, Nakaya S. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-Angstrom human C2-domain crystal structure. Blood . 2000; 96 979-987
34 Hay C R, Ludlam C A, Colvin B T. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost . 1998; 79 762-766
35 Saenko E L, Yakhyaev A V, Mikhailenko I, Strickland D K, Sarafanov A G. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem . 1999; 274 37685-37692
36 Schwarz H P, Lenting P J, Binder B. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood . 2000; 95 1703-1708
37 Lenting P J, Neels J G, van den Berg M B. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor related protein. J Biol Chem . 1999; 274 23734-23739
38 Anson D S, Choo K H, Rees D HJ. The gene structure of human antihemophilic factor IX. Embo J . 1984; 3 1053-1060
39 Giannelli F, Green P M, Sommer S S. Haemophilia B: database of point mutations and short additions and deletions-eighth edition. Nucleic Acids Res . 1998; 6 265-268
40 Giannelli F, Choo K H, Rees D JG. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature . 1983; 303 181-182
41 Thorland E C, Drost J B, Lusher J M. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia . 1999; 5 101-105
42 Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemost . 2000; 26 205-208
43 Kurachi S, Furukawa M, Salier J P. Regulatory mechanism of human factor IX gene: protein binding at the Leyden specific region. Biochemistry . 1994; 33 1580-1591
44 Morgan G E, Rowley G, Green P M. Further evidence for the importance of an androgen response element in the factor IX promotor. Br J Haematol . 1997; 98 79-85
45 Chu K, Wu S M, Stanley T, Stafford D W, High K A. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest . 1996; 98 1619-1625
46 Oldenburg J, Quenzel E M, Harbrecht U. Missense mutation at Ala-10 in the factor IX-propeptide: an insignificant variant in normal life but a decisive cause for bleeding during oral anticoagulant therapy. Br J Haematol . 1997; 98 240-244
47 Stanley T B, Humphries J, High K A, Stafford D W. Amino acids responsible for reduced affinities of vitamin K-dependent propeptides of the carboxylase. Biochemistry . 1999; 38 15681-15687
48 Oldenburg J, Kriz K, Wuillemin W A. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost . 2001; 85 454-457
49 Bajaj S P. Region of factor IXa protease domain that interacts with factor VIIIa: analysis of select hemophilia B mutants. Thromb Haemost . 1999; 82(Suppl) 218-225
50 Mertens K, Celie P HN, Kolkman J A, Lenting P J. Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly. Thromb Haemost . 1999; 82(Suppl) 209-217
51 Werner E J, Broxson E H, Tucker E L. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr . 1993; 123 893-898
52 Federici A B. Diagnosis of von Willebrand factor. Haemophilia . 1998; 4 654-660
53 Mancuso D J, Tuley E A, Westfield L A. Structure of the gene for human vWF. J Biol Chem . 1989; 264 19514-19527
54 Mancuso D J, Tuley E A, Westfield L A. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry . 1991; 30 253-269
55 Sadler J E. A revised classification of von Willebrand disease. Thromb Haemost . 1994; 71 520-525
56 Meyer D, Fressinaud E, Gaucher C. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from patient to the gene. Thromb Haemost . 1997; 78 451-456
57 Schneppenheim R, Budde U, Obser T. Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease. Blood . 2001; 97 2059-2066
58 Ruggeri Z M. Structure function of von Willebrand factor. Thromb Haemost . 1999; 82 576-584
59 Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood . 1989; 74 1591-1599
60 Gill J C, Endres-Brooks J, Bauer P J, Marks Jr J W, Montgomery R R. The effect of AB0 blood group on the diagnosis of von Willebrand disease. Blood . 1987; 69 1691-1695
61 Mohlke K L, Purkayastha A A, Westrick R J. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell . 1998; 96 111-120
62 Furan M, Lämmle B. Von Willebrand factor in thrombotic thrombocytopenic purpura. Thromb Haemost . 1999; 82 592-600
63 Huizinga E G, van der Plas M R, Kroon J, Sixma J J, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure . 1997; 5 1147-1156
64 Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem . 1998; 273 10396-10401
65 Al-Mondhiry H, Ehmann W C. Congental afibrinogenemia. Am J Hematol . 1994; 46 343-347
66 Cooper D N, Millar D S, Wacey A, Pemberton S, Tuddenham E GD. Inherited factor X deficiency: molecular genetics and pathophysiology. Thromb Haemost . 1997; 78 161-172
67 Oldenburg J, von Brederlow B, Fregin A. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost . 2000; 84 937-941
68 Salooja N, Martin P, Khair K, Liesner R, Hann I. Severe factor V deficiency and neonatal intracranial hemorrhage: a case report. Haemophilia . 2000; 6 44-46
69 Guasch J F, Leusen R P, Bertina R M. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is ``pseudohomozygous'' for activated protein C resistance. Thromb Haemost . 1997; 77 232-237
70 Seligsohn U. Factor XI deficiency. Thromb Haemost . 1993; 70 68-71
71 Bolton-Maggs P HB. The management of factor XI deficiency. Haemophilia . 1998; 4 683-688
72 Abbondanzo S L, Gootenberg J E, Lofts R S, McPherson R A. Intracranial hemorrhage in congenital deficiency of factor XIII. Am J Pediatr Hematol Oncol . 1988; 10 65-68
73 Nordstrom M, Lindblad B, Bergquist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Int Med . 1992; 232 155-160
74 Brown R D, Whisnant J P, Sicks J D, O'Fallon W M, Wiebers D O. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke . 1996; 27 373-380
75 Pabinger I, Bruckner S, Kyrle P A. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis . 1992; 3 547-553
76 Bayston T A, Lane D A. Antithrombin: molecular basis of deficiency. Thromb Haemost . 1997; 78 339-343
77 Tait R C, Walker I D, Reitsma P H. Prevalence of protein C deficiency in the healthy population. Thromb Haemost . 1995; 73 87-93
78 Reitsma P H. Protein C deficiency: from gene defects to disease. Thromb Haemost . 1997; 78 344-350
79 Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost . 1997; 78 351-356
80 Dahlbäck B, Catlsson M, Svensson P J. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A . 1993; 90 1004-1108
81 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem . 1994; 269 18735-18738
82 Zivelin A, Griffin J H, Xu X. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood . 1997; 89 397-401
83 Zivelin A, Rosenberg N, Faier S. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood . 1998; 92 1119-1124